Bioventus Inc. (BVS)
NASDAQ: BVS · Real-Time Price · USD
13.50
-0.34 (-2.46%)
Aug 31, 2026, 9:55 AM EDT - Market open
Bioventus Employees
Bioventus had 950 employees as of June 27, 2026. The number of employees did not change compared to the same quarter last year.
Employees
950
Change
n/a
Growth
n/a
Revenue / Employee
$612,472
Profits / Employee
$57,331
Market Cap
1.14B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 27, 2026 | 950 | 0 | - |
| Mar 28, 2026 | 940 | 10 | 1.08% |
| Dec 31, 2025 | 930 | 0 | - |
| Sep 27, 2025 | 950 | -80 | -7.77% |
| Jun 28, 2025 | 950 | -80 | -7.77% |
| Mar 29, 2025 | 930 | -65 | -6.53% |
| Dec 31, 2024 | 930 | -40 | -4.12% |
| Sep 28, 2024 | 1,030 | 60 | 6.19% |
| Jun 29, 2024 | 1,030 | 80 | 8.42% |
| Mar 30, 2024 | 995 | -45 | -4.33% |
| Dec 31, 2023 | 970 | -150 | -13.39% |
| Sep 30, 2023 | 970 | -190 | -16.38% |
| Jul 1, 2023 | 950 | -210 | -18.10% |
| Apr 1, 2023 | 1,040 | -110 | -9.57% |
| Dec 31, 2022 | 1,120 | -80 | -6.67% |
| Oct 1, 2022 | 1,160 | 260 | 28.89% |
| Jul 2, 2022 | 1,160 | 260 | 28.89% |
| Apr 2, 2022 | 1,150 | 250 | 27.78% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 2, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jul 3, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 3, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 26, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 27, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 2, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Enovis | 7,802 |
| QuidelOrtho | 6,500 |
| Integra LifeSciences Holdings | 4,427 |
| Lumexa Imaging Holdings | 4,335 |
| CONMED | 3,900 |
| Tandem Diabetes Care | 2,500 |
| Artivion | 1,800 |
| Alphatec Holdings | 913 |
BVS News
- 14 days ago - Bioventus price target raised to $19 from $15 at Canaccord - TheFly
- 25 days ago - Bioventus price target raised to $18 from $16 at Craig-Hallum - TheFly
- 25 days ago - Bioventus price target raised to $18 from $14 at Barrington - TheFly
- 25 days ago - Bioventus reports Q2 EPS 22c, consensus 22c - TheFly
- 25 days ago - Bioventus backs FY26 adjusted EPS view 75c-79c, consensus 78c - TheFly
- 25 days ago - Bioventus initiates review of strategic alternatives - TheFly
- 26 days ago - Bioventus Earnings Call Transcript: Q2 2026 - Transcripts
- 26 days ago - Bioventus Earnings release: Q2 2026 - Filings